rethinkPeptides Search
Menu
Study breakdown

The Clinical Future of Growth Hormone Secretagogues: Treatment, Diagnosis, and Beyond

ReviewModerate evidence
The takeaway

GH secretagogues have three main clinical futures: treating GH deficiency as an alternative to GH injections, diagnosing GH deficiency more reliably, and managing conditions beyond classical GH deficiency.

3 clinical futures

GH secretagogues may serve as treatments (replacing injections), diagnostics (better GH testing), and expanded therapies (aging, obesity, critical illness)

What the researchers found

GH secretagogues offer three clinical futures: oral GH deficiency treatment replacing injections, improved GH deficiency diagnostics, and expanded indications for partial GH insufficiency in aging, obesity, and critical illness.

Why it matters

GH deficiency affects quality of life in children and adults. Oral GH secretagogues that produce more natural GH release patterns could transform treatment from burdensome daily injections to simple pills.

How the study worked

Review of clinical data and future therapeutic directions for GH secretagogues, covering GHRP-6, hexarelin, ipamorelin, MK-677, and other compounds.

What this study cannot tell us

Review based on clinical data through 1999. Long-term efficacy and safety of chronic GH secretagogue use were not yet established. Regulatory approval pathways were uncertain.

How to read the evidence

Moderate evidence from a forward-looking review based on accumulating clinical trial data for multiple GH secretagogue compounds.

When this study was published

Published in 1999. While no oral GH secretagogue has been approved for GH deficiency, MK-677 and other compounds have been extensively studied.

The bigger picture

The clinical landscape for GH therapy could shift from injectable recombinant GH to oral secretagogues that stimulate the body's own GH production. This represents a paradigm shift from hormone replacement to hormone stimulation.

Questions still open

  • Will oral GH secretagogues achieve comparable efficacy to GH injections?
  • Can GH secretagogues serve as screening tools for adult GH deficiency?
  • How will the expanded indications beyond classical GH deficiency be validated?

Common questions

Could GH secretagogues replace GH injections?
Potentially. Oral compounds like MK-677 could provide the benefits of GH therapy through a daily pill instead of daily injections. This would be more convenient and could improve treatment adherence.
What conditions might GH secretagogues treat beyond GH deficiency?
Aging-related GH decline, obesity-associated GH suppression, critical illness muscle wasting, and possibly osteoporosis. These conditions involve partial GH insufficiency rather than complete deficiency.

Read the original research

Growth hormone secretagogues: the clinical future.

Hormone research, 51 Suppl 3, 29-33

Citation

Micic, D; Casabiell, X; Gualillo, O; Pombo, M; Dieguez, C; Casanueva, F F. (1999). Growth hormone secretagogues: the clinical future.. Hormone research, 51 Suppl 3, 29-33.